Stockscreener 앱 받기
0.2225
7.60%
-0.0183
전일 마감가:
$0.2408
열려 있는:
$0.252
하루 거래량:
976.13K
Relative Volume:
0.51
시가총액:
$2.25M
수익:
-
순이익/손실:
$-8.26M
주가수익비율:
-0.00415
EPS:
-53.609
순현금흐름:
$-12.17M
1주 성능:
-1.11%
1개월 성능:
-53.51%
6개월 성능:
-89.25%
1년 성능:
-98.14%
1일 변동 폭
$0.22
$0.252
1주일 범위
$0.2112
$0.27
52주 변동 폭
$0.19
$12.58
Gri Bio Inc Stock (GRI) Company Profile
명칭
Gri Bio Inc
전화
(619) 400-1171
주소
2223 AVENIDA DE LA PLAYA, LA JOLLA
GRI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
0.2225 | 2.44M | 0 | -8.26M | -12.17M | -53.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-09 | 개시 | H.C. Wainwright | Buy |
Gri Bio Inc 주식(GRI)의 최신 뉴스
GRI Bio conditionally regains Nasdaq compliance with equity listing rule By Investing.com - Investing.com Nigeria
GRI Bio conditionally regains Nasdaq compliance with equity listing rule - Investing.com
GRI Bio Regains Conditional Compliance With Nasdaq Listing Requirements - TipRanks
Short Covering: Is GCTSWS stock a good pick for beginnersJuly 2025 Chart Watch & Expert Approved Trade Ideas - baoquankhu1.vn
GRI Bio Shareholders Authorize Reverse Stock Split Plan - TipRanks
GRI Bio shareholders approve reverse stock split and report Nasdaq compliance - Investing.com
GRI Bio (NASDAQ: GRI) wins reverse split approval and addresses Nasdaq equity risk - Stock Titan
GRI: Reverse stock split and adjournment proposals approved; results to be filed on Form 8-K - TradingView — Track All Markets
Gains Recap: Why GRI Bio Inc stock remains on watchlistsJuly 2025 Big Picture & Low Risk Investment Opportunities - Bộ Nội Vụ
Options Flow: What insider trading reveals about GRI Bio Inc. stockEarnings Trend Report & Smart Money Movement Alerts - Bộ Nội Vụ
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Market Recap: What makes GRI Bio Inc stock attractive todayJuly 2025 Snapshot & Fast Moving Trade Plans - baoquankhu1.vn
GRI Bio approves reverse stock split, stockholders vote in favor - MSN
GRI Bio, Inc.Common Stock (NQ: GRI - FinancialContent
GRI Bio announces pricing of $8M public offering - MSN
GRI Bio increases at-the-market offering capacity to $7.38 million - Investing.com Australia
GRI Bio reports positive Phase 2a data for IPF treatment By Investing.com - Investing.com Nigeria
GRI Bio Expands At-The-Market Equity Offering Capacity - TipRanks
GRI Bio, Inc. Increases Share Issuance Limit - TradingView — Track All Markets
Can GRI Bio Inc. stock sustain institutional interestCushioning Options Review & trail grip notes for mixed terrain - ulpravda.ru
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Is GRI Bio Inc. stock affected by interest rate hikesWall Street Watch & Safe Entry Trade Signal Reports - Улправда
Can GRI Bio Inc. stock weather global recession2025 Price Targets & Community Consensus Trade Signals - ulpravda.ru
GRI Bio stock rises on positive Phase 2a immune data for IPF treatment - Investing.com
GRI Bio reports positive Phase 2a data for IPF treatment - Investing.com
GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621 - The Manila Times
GRI Bio, Inc. Announces Positive Phase 2a Trial Data for GRI-0621 - TradingView — Track All Markets
GRI Bio Announces Additional Positive Data from Phase 2a - GlobeNewswire
GRI Bio reports six-week interim safety outcomes from trial of GRI-0621 for IPF - MSN
What Wall Street predicts for GRI Bio Inc. stock priceBullish Engulfing Patterns & Small Entry Portfolio - Улправда
What technical signals suggest for GRI Bio Inc. stock2026 world cup usa national team third place match goalkeepers high defensive line group prediction insights - Улправда
What drives GRI Bio Inc stock priceEarnings Forecast Updates & High Yield Trading Growth - Early Times
Decliners Report: Is GRI Bio Inc stock attractive for hedge funds2025 Bull vs Bear & Free Community Consensus Stock Picks - moha.gov.vn
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
GRI Bio Inc. (GRI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What insider trading reveals about GRI Bio Inc. stockLong Setup & Real-Time Buy Zone Alerts - Улправда
Why GRI Bio Inc. stock remains on buy listsWeekly Trade Analysis & Weekly Setup with High ROI Potential - Улправда
Why GRI Bio Inc. stock could be next big winnerJuly 2025 Intraday Action & Expert Approved Momentum Ideas - DonanımHaber
What sentiment indicators say about GRI Bio Inc. stockWeekly Market Outlook & Weekly Momentum Stock Picks - Улправда
Oral therapy GRI-0621 boosts lung function, repairs tissue in IPF: Data - Pulmonary Fibrosis News
GRI Bio announces GRI-0621-IPF-02 trial met primary, secondary endpoints - MSN
GRI Bio Closes $8 Million Public Offering - The Globe and Mail
GRI Bio closes $8 million public offering of common stock and warrants - Investing.com Nigeria
GRI Bio closes $8 million public offering of common stock and warrants By Investing.com - Investing.com South Africa
GRI Bio (Nasdaq: GRI) details closing of offering, equity over $2.5M post-transaction - Stock Titan
GRI Bio Announces Closing of $8.0 Million Public Offering - GlobeNewswire
GRI Bio Launches $6.7 Million Public Offering - TipRanks
GRI Bio (NASDAQ: GRI) details $6.7M equity deal and runway into Q4 2026 - Stock Titan
GRI Bio prices $8 million public offering at $0.75 per share - Investing.com
GRI Bio’s IPF drug shows positive Phase 2a results with improved lung function - Investing.com India
Gri Bio Inc (GRI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):